A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS

Inclusion Criteria Concurrent Medication: Allowed: * Cimetidine. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: * Known history of intolerance or allergy to imidazoles or triazoles, or the non-azole components of clotrimazole troches (dextrose, cellulose, povidone, magnesium stearate). * Moderate or severe liver disease defined by specified lab values. Concurrent Medication: Excluded pending results of phase I studies to determine whether interaction between fluconazole and these agents occurs: * Barbiturates. * Phenytoin. * Coumarin-type anticoagulants. * Rifampin. * Oral hypoglycemics. * Cyclosporin. Patients with the following are excluded: * Known history of intolerance or allergy to imidazoles or triazoles, or the non-azole components of clotrimazole troches (dextrose, cellulose, povidone, magnesium stearate). * Unable to tolerate oral medication. * Moderate or severe liver disease defined by specified lab values. * Life expectancy \< 4 weeks. * Unable or unwilling to be followed at the same center for the conduct of this study. Prior Medication: Excluded within 3 days of study entry: * Other antifungal agents. * Excluded pending results of phase I studies to determine whether interaction between fluconazole and these agents occurs: * Barbiturates. * Phenytoin. * Coumarin-type anticoagulants. * Rifampin. * Oral hypoglycemics. * Cyclosporin. Patients meeting CDC criteria for diagnosis of AIDS, or having serologic or virologic evidence of HIV infection (but without AIDS-defining opportunistic infections as of yet). * Patients who have given informed consent in writing to their participation in the study. * Patients with signs of oropharyngeal candidiasis, i.e., with typical white plaques.